A European prospective observational study of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC): PREMISEHeather Payne, Marco De Santis, Ugo De Giorgi et al.|European Urology Open Science|2020Cited by 1
Pain outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving enzalutamide (ENZA) in a real-world setting: PREMISEDavid Mott, Marco Pavesi, Michael Herdman et al.|European Urology Open Science|2020Cited by 0